HIV viraemia and mother-to-child transmission risk after antiretroviral therapy initiation in pregnancy in Cape Town, South Africa.
about
Detectable Viral Load in Late Pregnancy among Women in the Rwanda Option B+ PMTCT Program: Enrollment Results from the Kabeho StudyOptimizing Antiretroviral Therapy (ART) for Maternal and Child Health (MCH): Rationale and Design of the MCH-ART Study.The Impact of Poxvirus Vector Priming, Protein Co-Administration, and Vaccine Intervals on HIV gp120 Vaccine-Elicited Antibody Magnitude and Function in Infant Macaques.Toward a universal antiretroviral regimen: special considerations of pregnancy and breast feeding.Viral Suppression and Retention in Care up to 5 Years After Initiation of Lifelong ART During Pregnancy (Option B+) in Rural Uganda.Frequency of Viremic Episodes in HIV-Infected Women Initiating Antiretroviral Therapy During Pregnancy: A Cohort Study.Advances in therapy for the prevention of HIV transmission from mother to child.Optimal timing of viral load monitoring during pregnancy to predict viraemia at delivery in HIV-infected women initiating ART in South Africa: a simulation study.Evaluation of universal versus genotype-guided efavirenz dose reduction in pregnant women using population pharmacokinetic modelling.Recent progress in immune-based interventions to prevent HIV-1 transmission to children.Optimizing prevention of HIV mother to child transmission: Duration of antiretroviral therapy and viral suppression at delivery among pregnant Malawian women.Challenges and successes in the implementation of option B+ to prevent mother-to-child transmission of HIV in southern Swaziland.Same-day antiretroviral therapy (ART) initiation in pregnancy is not associated with viral suppression or engagement in care: A cohort study.Implementation of Option B and a fixed-dose combination antiretroviral regimen for prevention of mother-to-child transmission of HIV in South Africa: A model of uptake and adherence to care
P2860
Q28555187-1A3F9987-FAE7-499E-857C-C46CA690EF4EQ37420114-5D3DDB39-2A2B-4904-BB86-50DDADDF5325Q38621582-68ADFD5A-04E4-4A6E-8DF0-18DB166AF1C3Q38828635-DE45DE84-157E-4B4C-8762-D8D58A3168DAQ38852269-02869EE1-19F8-49EA-9456-F612E67BFD3FQ39121804-7FE2BB9F-AF79-4ECF-A6F9-B8E123EE4C6FQ39234019-33304E37-C56B-4E15-BF86-9343A760E6EAQ46143181-2D9E7F05-1504-4411-8D6C-84C4AFD11C25Q46460183-0E39F869-3E1B-4B2E-B111-70E97B6B9FDEQ47560045-1C228DD8-FBD1-4334-9635-6BD8CE6CBAFAQ52610191-38A8C020-765B-4839-891D-6AC9EA651E0DQ52646486-DFB6424E-6267-400A-97AF-3944F12E3B4AQ55361139-BC068129-403D-4F78-8B2E-16423F4A505DQ58436064-085ED296-CBAB-469E-9201-6A40E7FBE2CF
P2860
HIV viraemia and mother-to-child transmission risk after antiretroviral therapy initiation in pregnancy in Cape Town, South Africa.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
HIV viraemia and mother-to-chi ...... cy in Cape Town, South Africa.
@en
HIV viraemia and mother-to-chi ...... cy in Cape Town, South Africa.
@nl
type
label
HIV viraemia and mother-to-chi ...... cy in Cape Town, South Africa.
@en
HIV viraemia and mother-to-chi ...... cy in Cape Town, South Africa.
@nl
prefLabel
HIV viraemia and mother-to-chi ...... cy in Cape Town, South Africa.
@en
HIV viraemia and mother-to-chi ...... cy in Cape Town, South Africa.
@nl
P2093
P2860
P921
P356
P1433
P1476
HIV viraemia and mother-to-chi ...... ncy in Cape Town, South Africa
@en
P2093
E J Abrams
J A McIntyre
L-G Bekker
T K Phillips
P2860
P356
10.1111/HIV.12397
P577
2016-06-28T00:00:00Z